Yazılar

Spotify Founder Daniel Ek Shifts Focus from Music to European Tech “Moonshots”

When Daniel Ek launched Spotify in 2006, the music world was in turmoil — piracy was rampant, CD sales were collapsing, and even Apple’s iTunes was struggling to convince listeners to pay per song. Ek, a 23-year-old coder from Stockholm, bet on a radical idea: that streaming, not downloading, would save the industry. Nearly two decades later, Spotify is used by almost 750 million people worldwide, valued at $140 billion, and credited with reshaping how the world listens to music.

Now, Ek says it’s time for his next act. The entrepreneur, who will step down as Spotify’s CEO in 2026, told Reuters that he wants to devote himself to deep technology, AI, and health innovation — sectors he believes can redefine Europe’s role in global tech.

“Big challenges often appear impossible until someone decides to tackle them,” Ek said. “At Spotify, we started with what felt like an impossible idea. Nearly 20 years later, what once looked unreasonable is now obvious.”

Ek plans to focus on early-stage European startups through his investment firm Prima Materia, pledging €1 billion ($1.18 billion) of his personal wealth to fund what he calls “moonshot projects” — companies tackling major problems like climate change, healthcare, and artificial intelligence.

TECH ENTREPRENEUR TURNED HEALTH AND DEFENCE INVESTOR

Ek already has a foothold in those areas. In 2018, he co-founded Neko Health, a preventive health-tech firm focused on early detection through AI scanning systems. The company has raised $325 million to date.

He has also invested in Helsing, Europe’s largest defence startup, valued at $12 billion after securing over $1 billion in funding to develop AI-controlled military systems. Helsing says its technology is used for defence purposes in Ukraine and Europe, not for offensive warfare.

The Helsing investment has stirred controversy in the music world. Bands such as Massive Attack and King Gizzard & the Lizard Wizard have removed their music from Spotify, saying Ek’s involvement in war technology undermines the platform’s artistic mission.

“Music and weapons are not a good mix,” said Simon Dyson, analyst at Omdia, adding that the backlash could become “a distraction” for Spotify’s brand.

Spotify declined to comment directly on Ek’s defence investments.

FROM CODER TO INDUSTRY DISRUPTOR

Raised in a Stockholm suburb, Ek began coding in his teens and built several startups before teaming up with Martin Lorentzon to found Spotify. His model — a mix of paid subscriptions and ad-supported streaming — lured users away from piracy and reshaped the global music economy.

Under Ek’s leadership, Spotify became not just a streaming service but a cultural platform: algorithmic playlists created overnight stars, podcasts expanded the company’s reach, and its subscription model became a blueprint for digital media worldwide.

Ek’s influence extends beyond business. Supporters hail him as the visionary who saved the music industry; critics argue that Spotify’s economics still favor major labels over independent artists. But few dispute his impact.

LOOKING BEYOND SPOTIFY

Ek, now 42, says he will remain executive chair of Spotify, guiding strategy while pursuing his new ventures.

“My co-founder likes to say that the value of a company is the sum of all problems solved,” he said. “Progress often comes from those willing to go against conventional wisdom.”

For the man who turned music into a utility, the next challenge is to turn Europe into a hub for world-changing technology — and perhaps create another “impossible idea” that becomes obvious in hindsight.

Digital Health Companies Struggle in 2024 Amid Post-Covid Adjustments

The year 2024 has been a tough one for digital health companies, marking a stark contrast to the boom times of the Covid era. While the Nasdaq soared 32%, surpassing 20,000 for the first time this month, digital health stocks have mostly suffered. Of 39 public companies in this sector analyzed by CNBC, approximately two-thirds have seen significant declines, with some even going out of business.

However, there have been a few success stories, including Hims & Hers Health, which benefited from its new weight loss program and its positioning within the GLP-1 craze. Despite these exceptions, the sector as a whole faced challenges. According to Scott Schoenhaus, an analyst at KeyBanc Capital Markets, 2024 marked a “year of inflection” for the industry. The pandemic-driven surge in demand has slowed, and businesses are now focusing on profitability in a more subdued growth environment.

During the pandemic, digital health startups raised record-breaking funds, with $29.1 billion secured in 2021 alone, and numerous companies went public. However, with the pandemic’s worst waves behind, the demand for digital health tools has cooled. As a result, many companies are rethinking their business models, with mixed outcomes.

Companies like Progyny, a fertility and family planning benefits provider, have seen a dramatic 60% decline in their stock prices, while Teladoc Health, once a leader in virtual care, has seen its stock plummet by 58%, and is 96% off its 2021 high. Teladoc’s market cap, which once stood at $37 billion after acquiring Livongo in 2020, is now under $1.6 billion. Similarly, GoodRx, which offers medication price transparency, is down 33% year-to-date.

The year saw several companies adjust their revenue forecasts, with Progyny and GoodRx repeatedly lowering their full-year guidance. In the case of Teladoc, the company withdrew its 2024 revenue outlook after experiencing consecutive declines.

Dexcom, a diabetes management device company, also faced challenges, with its stock dropping 35% in 2024, including a 40% plunge in July after disappointing results. Genetic testing company 23andMe had an especially difficult year, with its stock down more than 80%. The company’s post-SPAC valuation has fallen from $3.5 billion to under $100 million, and it has had to restructure its workforce and shut down its therapeutics business.

Despite these setbacks, some companies have thrived. Hims & Hers, for instance, saw its stock surge by over 200%, reaching a market cap of $6 billion. The company’s success was driven by high demand for GLP-1 drugs, particularly compounded semaglutide, a more affordable alternative to expensive treatments like Ozempic and Wegovy. Doximity, a digital platform for medical professionals, also had a strong year, with its stock more than doubling.

Oscar Health, a tech-enabled insurance provider, also performed well, with shares up nearly 50% in 2024. The company has been expanding rapidly, supporting around 1.65 million members with plans to reach 4 million by 2027.

Additionally, two companies, Waystar and Tempus, went public in 2024. Waystar, a healthcare payment software vendor, saw its stock rise significantly post-IPO, while Tempus, a precision medicine company, saw a slight decline.

Despite these bright spots, the sector has witnessed several exits. Companies like Cue Health and Better Therapeutics have shut down, and large-scale acquisitions occurred, such as the $8.9 billion acquisition of R1 RCM by TowerBrook Capital Partners and Clayton, Dubilier & Rice. Digital health companies like Commure and Augmedix were also involved in acquisitions.

As the digital health sector adjusts to a post-pandemic reality, industry experts believe the future lies in refining business models. Michael Cherny, an analyst at Leerink Partners, emphasized that digital health companies need to focus on achieving the “triple aim” of healthcare: better care, more convenience, and lower costs, if they are to succeed in the long term.

 

Apple to Introduce Satellite Communications and Blood Pressure Monitoring to Apple Watch

Apple is reportedly planning to integrate satellite communication capabilities into its Apple Watch by 2025, as well as introducing a blood-pressure monitoring feature, according to a Bloomberg News report on Tuesday.

The satellite communication feature is expected to debut in the 2025 iteration of the Apple Watch Ultra. This capability will allow users to send messages without relying on cellular or internet connections, leveraging Apple’s ongoing advancements in satellite technology. Apple initially brought satellite connectivity to its iPhones in 2022 and recently invested $1.5 billion into satellite provider Globalstar to enhance these services further.


HEALTH-FOCUSED INNOVATIONS

In addition to satellite communication, Apple is reportedly ramping up development on a blood-pressure monitoring feature for its smartwatch. This medical functionality is also anticipated to launch in 2025. Apple has been steadily expanding the health-related capabilities of its devices, aiming to provide users with tools for long-term health tracking and emergency response.

In September, Apple introduced a new smartwatch model that can detect conditions such as sleep apnea and alert users to emergencies. These developments align with the company’s broader push to make its devices integral to users’ health and wellness routines.


MARKET IMPACT AND OUTLOOK

Apple’s latest innovations underscore its strategy to blend advanced technology with health-focused features, aiming to further entrench its ecosystem in consumers’ daily lives. Satellite connectivity on the Apple Watch would enhance its utility in areas with limited cellular coverage, appealing to outdoor enthusiasts and adventurers.

While the company did not immediately respond to requests for comment, these anticipated features are expected to position Apple strongly in the wearable tech and health device markets, reinforcing its leadership in both sectors.